Over the past several decades, downregulation of certain cytokines/chemokines in several immune cell types was considered to be a common approach to AD treatment and, indeed, the molecules targeting specific immunomodulatory pathways such as interleukin-2 (IL-2) and TNF-α demonstrated the effectiveness of this approach [36,37,38]. Here, IL2 is linked to Alzheimer disease.